


PRODUCT INFORMATION



Ulipristal Acetate-d₆

Item No. 26446

CAS Registry No.: 1621894-64-1
Formal Name: 17-(acetyloxy)-11β-[4-[di(methyl-d₃) amino]phenyl]-19-norpregna-4,9-diene-3,20-dione
MF: C₃₀H₃₁D₆NO₄
FW: 481.7
Chemical Purity: ≥98% (Ulipristal Acetate)
Deuterium Incorporation: ≥99% deuterated forms (d₁-d₆); ≤1% d₀
Supplied as: A solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Ulipristal acetate-d₆ is intended for use as an internal standard for the quantification of ulipristal acetate (Item No. 23657) by GC- or LC-MS. The accuracy of the sample weight in this vial is between 5% over and 2% under the amount shown on the vial. If better precision is required, the deuterated standard should be quantitated against a more precisely weighed unlabeled standard by constructing a standard curve of peak intensity ratios (deuterated versus unlabeled).

Ulipristal acetate-d₆ is supplied as a solid. A stock solution may be made by dissolving the ulipristal acetate-d₆ in the solvent of choice, which should be purged with an inert gas. Ulipristal acetate-d₆ is soluble in the organic solvent methanol, which should be purged with an inert gas.

Description

Ulipristal acetate is a selective progesterone receptor modulator (SPRM) that binds to the human progesterone receptors PR-A and PR-B (EC₅₀s = 8.5 and 7.7 nM, respectively), rabbit uterine PR (EC₅₀ = 13.6 nM), and rabbit thymic glucocorticoid receptor (GR; EC₅₀ = 15.4 nM).¹ It is selective for human progesterone receptors over the human estrogen receptor (ER; EC₅₀ = >10,000 nM). It inhibits growth of IGROV-1 and SKOV3 human ovarian cancer cells (IC₅₀s = 15.5 and 31.5 μM, respectively) even after resistance to combined cisplatin (Item No. 13119) and paclitaxel (Item No. 10461) treatment has developed.² Ulipristal acetate reverses the proliferative effect of progesterone on patient-derived germline mutant *BRCA1* breast tissue xenografts in ovariectomized athymic mice.³ Ulipristal acetate (40 mg/kg, i.p.) administered to female mice within 6 hours of human chorionic gonadotropin (hCG) treatment inhibits ovulation.⁴ Formulations containing ulipristal acetate have been used as emergency contraceptives and to treat uterine fibroids.

References

1. Attardi, B.J., Burgenson, J., Hild, S.A., et al. *J. Steroid Biochem. Mol. Biol.* **88**(3), 277-288 (2004).
2. Gamarra-Luques, C.D., Hapon, M.B., Goyeneche, A., et al. *J. Ovarian Res.* **7**:45, (2014).
3. Communcal, L., Vilasco, M., Hugon-Rodin, J., et al. *Oncotarget* **7**(29), 45317-45330 (2016).
4. Nallasamy, S., Kim, J., Sitruk-Ware, R., et al. *Reprod. Sci.* **20**(4), 371-381 (2013).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 03/09/2023

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM